Long-acting mild anti-wrinkle supramolecular polypeptide composition, preparation method and application thereof

Abstract

The present application belongs to the field of cosmetics, and provides a long-acting mild anti-wrinkle supramolecular polypeptide composition, a preparation method and application thereof. The composition comprises a botulinum-like polypeptide with anti-wrinkle effect, a polypeptide with the effect of promoting the growth of skin cell collagen, a polypeptide with the effects of soothing, anti-allergy and anti-inflammation, and a supramolecular ionic liquid with the effect of penetration promotion. The long-acting mild anti-wrinkle supramolecular composition provided by the present application is centered on the three targets of anti-skin aging: smoothing fine lines, tightening skin and resisting inflammation, and at the same time, the soothing and anti-allergy effects which are not possessed by traditional anti-wrinkle skin care products are taken into account, so as to fully meet the needs of consumers with different skin conditions; on the basis of self-assembly of polypeptides into supramolecular structures, the stable compounding of 10 kinds of functional polypeptides is completed through a reasonable preparation method and proportion, and the problem of poor compatibility of functional components is solved; on the basis of the supramolecular structure, the supramolecular ionic liquid is combined for further penetration and delivery, and the synergistic effect also effectively protects the inner supramolecular polypeptide structure.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of cosmetics, and particularly relates to a long-acting mild anti-wrinkle supramolecular polypeptide composition and a preparation method and application thereof. BACKGROUND

[0002] The information disclosed in this Background section is for the purpose of generally presenting the context of the application. The information disclosed in this Background section is not to be taken as an acknowledgement or any form of suggestion that this information forms prior art.

[0003] In the current cosmetic market, anti-aging and anti-wrinkle skin care products account for an increasingly high proportion. Consumers expect high-efficiency skin care products to smooth fine lines and tighten skin, but are worried that excessive use will cause secondary damage to the skin. Even some sensitive skin consumers are too worried about the irritation of anti-aging and anti-wrinkle skin care products and cannot find suitable anti-aging and anti-wrinkle skin care products.

[0004] Polypeptide cosmetic raw materials are widely used in various skin care products due to their high biocompatibility and good efficacy. However, due to solubility and formulation stability of raw materials, multiple polypeptides cannot be used simultaneously in skin care products. SUMMARY

[0005] To solve the above problems, the present application provides a preparation method and application of a long-acting mild anti-wrinkle supramolecular composition. The present application focuses on the effects of anti-wrinkle, anti-inflammatory and soothing, and uses the self-assembly characteristics of amphiphilic polypeptides to prepare a supramolecular composition of 10 different types of polypeptides with good anti-wrinkle effect, which can also protect and repair the skin, suitable for consumers of all types of skin.

[0006] To achieve the above purpose, the present application adopts the following technical solutions:

[0007] The first aspect of the present application provides a long-acting mild anti-wrinkle supramolecular polypeptide composition, which is composed of the following raw materials by weight percentage: botulinum-like polypeptide 0.013%-0.015%, collagen growth promoting peptide 0.061%-0.065%, soothing peptide 0.01%-0.015%, anti-inflammatory peptide 0.005%-0.008%, supramolecular ionic liquid 5%-8%, active ingredient 32%-35%, and the rest is water.

[0008] The long-acting mild anti-wrinkle supramolecular composition provided by the present application comprises a botulinum-like polypeptide having an anti-wrinkle effect, a polypeptide having a skin cell collagen growth promoting effect, a polypeptide having soothing, anti-allergy and anti-inflammatory effects, and a supramolecular ionic liquid having a penetration promoting effect. The long-acting mild anti-wrinkle supramolecular composition provided by the present application focuses on the three major targets of anti-skin aging: smoothing fine lines, tightening skin, and resisting inflammation, while also considering the soothing and anti-allergy effects that traditional anti-wrinkle skin care products lack, thereby fully meeting the needs of consumers with different skin types; based on the self-assembly of polypeptides into supramolecular structures, the stable compounding of 10 functional polypeptides is achieved through a reasonable preparation method and proportion, thereby solving the problem of poor compatibility of functional components; on the basis of the supramolecular structure, the supramolecular ionic liquid is further used for penetration and delivery, thereby achieving synergistic effect and effectively protecting the inner supramolecular polypeptide structure.

[0009] In some embodiments, the botulinum-like polypeptide comprises: arginine / lysine polypeptide and acetyl hexapeptide-1.

[0010] In some embodiments, the collagen growth promoting peptide comprises: palmitoyl tripeptide-1, palmitoyl tripeptide-5, palmitoyl pentapeptide-4, tripeptide-1, decapeptide-4 and hexapeptide-9.

[0011] In some embodiments, the soothing peptide is acetyl heptapeptide-4.

[0012] In some embodiments, the anti-inflammatory peptide is palmitoyl tetrapeptide-7.

[0013] In some embodiments, the supramolecular ionic liquid is one or two of glycerol-betaine, betaine-propylene glycol and betaine-citric acid.

[0014] In some embodiments, the active ingredient is one or two of 1,2-hexanediol, glycerol and 1,2-pentanediol.

[0015] In a second aspect, the present application provides a preparation method of a long-acting mild anti-wrinkle supramolecular polypeptide composition, comprising:

[0016] Take palmitoyl tripeptide-1, palmitoyl tripeptide-5 and palmitoyl pentapeptide-4, dissolve them in water, ultrasonic dispersion, adjust the pH value to 4-5.5, and obtain solution 1;

[0017] Take tripeptide-1, decapeptide-4, hexapeptide-9, arginine / lysine polypeptide and acetyl hexapeptide-1, dissolve them in water, and obtain solution 2;

[0018] Add solution 2 to solution 1 under stirring, and stand at room temperature for 3-6 hours to obtain solution 3;

[0019] Mixing the supramolecular ionic liquid and the active ingredient, ultrasonic dispersion, adding palmitoyl tetrapeptide-7 and acetyl heptapeptide-4, heating at 30-50 DEG C for 10-20 min, to obtain solution 4;

[0020] Adding solution 3 to solution 4 under stirring conditions, high-pressure microjet treatment, to obtain.

[0021] In some embodiments, the stirring speed is 50-500 rpm;

[0022] In some embodiments, the pressure of the high-pressure microjet is 10000-20000 psi, and the treatment is 2-3 times.

[0023] The palmitoyl polypeptide has an amphiphilic structure and can form a stable self-assembled supramolecular structure under certain conditions, and the self-assembly properties of palmitoyl tripeptide-1, palmitoyl tripeptide-5 and palmitoyl pentapeptide-4 are combined with botulinum-like polypeptides and other collagen growth-promoting peptides to form stable supramolecules in water, thereby improving the compatibility and stability of multiple polypeptide combinations, and the supramolecular structure can improve the transdermal permeability, so that the botulinum-like polypeptides and the collagen growth-promoting peptides can smoothly enter the deep layer of the skin, thereby playing a better role in smoothing fine lines and tightening the skin.

[0024] The soothing peptide and the anti-inflammatory peptide are dissolved in the supramolecular ionic liquid, and after sufficient action of the supramolecular solvent, nanoscale peptide particles with higher dispersibility are also generated in the solvent, thereby improving the transdermal permeability of the soothing peptide and the anti-inflammatory peptide.

[0025] The self-assembled supramolecular polypeptide is added to the supramolecular ionic liquid, and the supramolecular ionic liquid is used for further penetration and delivery, so that the penetration effect is better, and after high-pressure microjet treatment, the supramolecular ionic liquid can wrap and protect the self-assembled supramolecular polypeptide, thereby synergistically improving the stability of the active ingredients and further improving the stability of the composition.

[0026] In a third aspect, the application provides a use of the long-acting mild anti-wrinkle supramolecular polypeptide composition in the preparation of cosmetics.

[0027] Advantages of the application

[0028] (1) The application is centered on the three targets of anti-skin aging: smoothing fine lines, tightening the skin, and resisting inflammation, and also takes into account the soothing and anti-allergic effects that traditional anti-wrinkle skin care products do not have, thereby fully meeting the needs of consumers with different skin types; based on the self-assembly of polypeptides into supramolecular structures, the stable combination of 10 functional polypeptides is achieved through a reasonable preparation method and proportion, thereby solving the problem of poor compatibility of functional components; on the basis of the supramolecular structure, the supramolecular ionic liquid is combined for further penetration and delivery, thereby synergistically improving the inner supramolecular polypeptide structure.

[0029] (2) The present application research and development found that the solubility stability of 10 heavy-duty efficacy polypeptides is not good after direct compounding. Therefore, through systematic research and experimental exploration, the present application found that the self-assembly characteristics of palmitoyl tripeptide-1, palmitoyl tripeptide-5 and palmitoyl pentapeptide-4 can form stable supramolecules with botulinum-like polypeptides and other collagen growth promoting peptides in water, which significantly improves the compatibility and solubility stability of multiple polypeptide compounding. At the same time, this supramolecular structure can improve the transdermal permeability, so that botulinum-like polypeptides and collagen growth promoting peptides can smoothly enter the deep layer of the skin, and play a better role in smoothing fine lines and tightening the skin.

[0030] (3) The preparation method of the present application is simple, practical and easy to popularize. BRIEF DESCRIPTION OF DRAWINGS

[0031] The accompanying drawings, which form a part of this specification, are included to provide a further understanding of the application and are incorporated in and constitute a part of this specification. The embodiments of these drawings are set forth to explain the present application and do not constitute any improper limitation on the present application.

[0032] Figure 1 Example 1 sample;

[0033] Figure 2 Comparative Example 1 sample;

[0034] Figure 3 Comparative Example 2 content distribution diagram at different depths of the skin;

[0035] Figure 4 Example 1 content distribution diagram at different depths of the skin. DETAILED DESCRIPTION

[0036] It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the present application. Unless otherwise indicated, all technical and scientific terms used in the present application have the same meaning as generally understood by those skilled in the art to which the present application belongs.

[0037] The present application will be further described in detail below in conjunction with specific examples. It should be noted that the specific examples are an explanation of the present application rather than a limitation.

[0038] Example 1

[0039] The formula of the long-acting mild supramolecular polypeptide composition of the present embodiment is shown in Table 1:

[0040] Table 1 Formula of long-acting mild supramolecular polypeptide composition of Example 1

[0041]

[0042]

[0043] The configuration method is as follows:

[0044] Palmitoyl tripeptide-1, palmitoyl tripeptide-5 and palmitoyl pentapeptide-4 are dissolved in deionized water in a formula amount of 30% by proportion, ultrasonic dispersion is performed for 10 min, and the pH value is adjusted to 4-5.5 to obtain solution 1;

[0045] Tripeptide-1, decapeptide-4, hexapeptide-9, arginine / lysine polypeptide and acetyl hexapeptide-1 are dissolved in deionized water in a formula amount of 32.911% by proportion to obtain solution 2;

[0046] Solution 2 is added to solution 1 under stirring, and is left to stand at room temperature for 4 h to obtain solution 3;

[0047] Betaine-citric acid, glycerol and 1,2-hexanediol are taken in an emulsifying kettle, ultrasonic dispersion is performed for 10 min, and then palmitoyl tetrapeptide-7 and acetyl heptapeptide-4 are added, and heating is performed at 40°C for 20 min to obtain solution 4;

[0048] Solution 3 is added to solution 4 under stirring, and is subjected to high-pressure microjet treatment, and is treated twice at 15000 Psi to obtain the long-acting mild anti-wrinkle supermolecular polypeptide composition.

[0049] Example 2

[0050] The formula of the long-acting mild supermolecular polypeptide composition of this example is shown in Table 2:

[0051] Table 2 Formula of the long-acting mild supermolecular polypeptide composition of Example 2

[0052] Component Name Content / % Palmitoyl tripeptide-1 0.01 Palmitoyl tripeptide-5 0.01 Palmitoyl pentapeptide-4 0.02 Tripeptide-1 0.005 Decapeptide-4 0.01 Hexapeptide-9 0.006 Arginine / lysine polypeptide 0.003 Acetyl hexapeptide-1 0.01 Palmitoyl tetrapeptide-7 0.005 Acetyl heptapeptide-4 0.01 Betaine-propylene glycol 5 Glycerin 30 1,2-hexanediol 2 Deionized water 62.911

[0053] The configuration method is as follows:

[0054] Palmitoyl tripeptide-1, palmitoyl tripeptide-5 and palmitoyl pentapeptide-4 are dissolved in deionized water in a formula amount of 30% by proportion, ultrasonic dispersion is performed for 10 min, and the pH value is adjusted to 4-5.5 to obtain solution 1;

[0055] Tripeptide-1, decapeptide-4, hexapeptide-9, arginine / lysine polypeptide and acetyl hexapeptide-1 are dissolved in deionized water in a formula amount of 32.911% by proportion to obtain solution 2;

[0056] Solution 2 is added to solution 1 under stirring, and is left to stand at room temperature for 5 h to obtain solution 3;

[0057] Betaine-propylene glycol, glycerol and 1,2-hexanediol are taken in an emulsifying kettle, ultrasonic dispersion is performed for 10 min, and then palmitoyl tetrapeptide-7 and acetyl heptapeptide-4 are added, and heating is performed at 35°C for 20 min to obtain solution 4;

[0058] Solution 3 is added to solution 4 under stirring, and is treated by high-pressure microjet, 2 times at 15000 Psi, to obtain the long-acting mild anti-wrinkle supramolecular polypeptide composition.

[0059] Comparative Example 1

[0060] The difference between the preparation method of Example 1 and Comparative Example 1 is that the preparation method of Comparative Example 1 is as follows:

[0061] The polypeptides are weighed according to the formula, and the formula amount of glycerol, 1,2-hexanediol and deionized water is added, and the mixture is obtained by stirring and ultrasonic treatment.

[0062] Comparative Example 2

[0063] The difference between the formula of Example 1 and Comparative Example 2 is that no betaine-citric acid is added, and the preparation method is as follows:

[0064] Palmityl tripeptide-1, palmityl tripeptide-5 and palmityl pentapeptide-4 are dissolved in 30% deionized water according to the formula, ultrasonic dispersion is performed for 10 min, and the pH value is adjusted to 4-5.5 to obtain solution 1;

[0065] Tripeptide-1, decapeptide-4, hexapeptide-9, arginine / lysine polypeptide and acetyl hexapeptide-1 are dissolved in 32.911% deionized water according to the formula to obtain solution 2;

[0066] Solution 2 is added to solution 1 under stirring, and is placed at room temperature for 4 h to obtain solution 3;

[0067] Glycerol and 1,2-hexanediol are taken in an emulsifying kettle, and palmityl tetrapeptide-7 and acetyl heptapeptide-4 are added, heated at 40°C for 20 min to obtain solution 4;

[0068] Solution 3 is added to solution 4 under stirring, and is treated by high-pressure microjet, 2 times at 15000 Psi, to obtain the long-acting mild anti-wrinkle supramolecular polypeptide composition.

[0069] Comparative Example 3

[0070] The difference between the preparation method of Example 1 and Comparative Example 3 is that no high-pressure microjet treatment is performed.

[0071] Comparative Example 4

[0072] The difference between the formula of Example 2 and Comparative Example 4 is that no soothing peptide acetyl heptapeptide-4 is added, and the preparation method is consistent.

[0073] Comparative Example 5

[0074] The difference between Example 1 and Comparative Example 5 is that no palmityl tripeptide-1 is added.

[0075] Comparative Example 6

[0076] The difference from Example 1 is that palmitoyl tripeptide-5 is not added.

[0077] Comparative Example 7

[0078] The difference from Example 1 is that palmitoyl pentapeptide-4 is not added.

[0079] Stability evaluation of Experiment Example 1

[0080] The stability of the compositions of Example 1 and Comparative Example 1 was tested;

[0081] See the instruction manual for results. Figure 1 and Figure 2 , and Table 3 below.

[0082] Figure 1 A photograph of the long-lasting, mild anti-wrinkle supramolecular peptide composition of Example 1 is shown. Figure 1 As can be seen, Example 1 is clear and transparent, with no insoluble matter or other impurities visible.

[0083] Figure 2 A photograph of the polypeptide composition of Comparative Example 1 is shown. Figure 2 It can be seen that the polypeptide in Comparative Example 1 was not completely dissolved, and there were still insoluble substances.

[0084] This demonstrates that there are difficulties in compounding multiple peptides, and the long-acting, mild, anti-wrinkle supramolecular peptide composition provided in the embodiments of the present invention cannot be obtained simply by mixing them.

[0085] Stability experiments were conducted on the supramolecular polypeptide compositions prepared in Examples 1, 5, 6, and 7. Samples were placed under refrigeration (2-8°C), room temperature, and high temperature (40°C) for a certain period of time, and their appearance was observed. The results are shown in Table 3. The stability experiments revealed that the supramolecular polypeptide composition of Example 1 prepared according to the method of this invention exhibits high stability. Furthermore, it was found that when one polypeptide was missing from the substrate self-assembled polypeptide combination, although a supramolecular polypeptide composition could be prepared, its long-term stability could not be guaranteed. This indicates that the palmitoyl amphiphilic polypeptide combination selected in the preparation method of this invention—palmitoyl tripeptide-1, palmitoyl tripeptide-5, and palmitoyl pentapeptide-4—has a better stabilizing effect on the decapolypeptide composition system.

[0086] Table 3 Stability Test Results

[0087]

[0088] Experimental Example 2: Cytotoxicity Evaluation

[0089] According to GB / T 16886.5-2017 / ISO 10993-5:2009 "Biological evaluation of medical devices - Part 5: In vitro cytotoxicity tests", the long-acting mild anti-wrinkle supramolecular polypeptide composition prepared in Examples 1 and 2 in the application is subjected to in vitro cytotoxicity test to verify the biocompatibility.

[0090] The MTT cytotoxicity test evaluation method is selected, the L929 cell line is selected, the 10% DMSO solution is used as the positive control group, the 3% fetal calf serum culture medium is used as the negative control group, the test group is the 3% fetal calf serum culture medium leaching solution added with the tested sample, and the tested sample is added in an amount of 0.2 g / mL and is cultured at 37°C for 24 h.

[0091] The specific experimental steps are as follows:

[0092] (1) The L929 cells cultured for 48 h are prepared into a cell suspension of 1×10 5 cells / mL with a cell culture solution for standby;

[0093] (2) The 1×10 5 cell suspension is inoculated into a 96-well cell culture plate (100 μL / well), and is placed in a 37°C, 5% CO2 incubator for culture for 24 h to form a semi-confluent monolayer;

[0094] (3) After 24 h, the original culture solution is discarded, and then 100 μL of sample leaching solution, positive control solution and negative control solution are added, respectively, 5 wells for each group, and are placed in a 37°C, 5% CO2 incubator for culture for 24 h.

[0095] (4) 50 μL of MTT solution is added to each well, and then incubation is continued at 37°C, 5% CO2 for 2 h;

[0096] The MTT solution is discarded, 100 μL of DMSO solution is added to each well, the plate is shaken, and the absorbance at 570 nm is measured on a microplate photometer, and the cell proliferation rate (RGR, %) is calculated, and the cytotoxicity is evaluated according to the following Table 4.

[0097] Table 4 In vitro cytotoxicity grading table

[0098] Level Relative proliferation degree / % 0 ≥100 1 75-99 2 50-74 3 25-49 4 1-24 5 0

[0099] The experimental results are shown in Table 5, and the cytotoxicity of the long-acting mild anti-wrinkle supramolecular polypeptide composition prepared in the application is 1, which indicates that it has good biocompatibility and will not produce toxicity when applied to the skin.

[0100] Table 5 Cytotoxicity test results

[0101] Sample Toxicity level Example 1 1 Example 2 1 Positive control group 5

[0102] Experimental Example 3 Transdermal Test

[0103] To verify the skin penetration effect of the long-acting, gentle, anti-wrinkle supramolecular polypeptide composition described in this invention, the following transdermal test experiment was conducted:

[0104] According to GB / T40219-2021 "General Specifications for Raman Spectrometers" and the laboratory's internal standard methods, the skin penetration effects of the polypeptide compositions prepared in Example 1, Example 2, Comparative Example 2 and Comparative Example 3 were compared and tested.

[0105] The test involved one person and the test area consisted of five 1*1cm blocks. 2 The test area of ​​the skin was measured, and two points were selected in each test area for parallel testing five times. The LabRAM Odyssey high-resolution microscope confocal Raman spectrometer was used to perform the tests at time points of 0.5h, 1h, 2h, 4h and 6h.

[0106] The test environment was maintained at a temperature of 22℃±2℃ and a humidity of 50%±10%. The tester cleaned the test area with water, then sat quietly in the temperature and humidity controlled room for 30 minutes. Samples were then applied to the test areas; four areas were coated with samples from Example 1, Example 2, Comparative Example 2, and Comparative Example 3, respectively, while the remaining area was coated with water as a blank control. Tests were then conducted according to the experimental time points.

[0107] After Raman spectroscopy testing, Labspec software was used to perform baseline calibration and confirm the positions of characteristic peaks in the Raman spectra, and data calculations were performed. The permeability behavior of the sample was determined by the characteristic Raman signal that distinguishes the product from the intrinsic signal of the skin, confirming its distribution at different skin depths. The relative permeability was measured as the ratio of the total Raman spectral intensity of the tracking active ingredient that has penetrated into the skin to the total Raman spectral intensity of the active ingredient applied to the skin. The relative permeability results are shown in Table 6.

[0108] Table 6. Relative permeability results of different samples

[0109]

[0110] It can be seen from Table 6. By comparing Example 1 with Comparative Example 2, it can be seen that when no supramolecular solvent is added, the penetration effect of the pure 10-peptide composition is general; by comparing Example 1 with Comparative Example 3, it can be seen that when no high-pressure microfluidization is used for the final treatment, the ordinary supramolecular polypeptide composition cannot achieve the expected penetration effect, and the long-acting mild anti-wrinkle supramolecular polypeptide composition prepared by the method of the present application has excellent skin penetration, and this effect is derived from the product obtained by the self-assembly of the supramolecular polypeptide assisted by the supramolecular solvent, and the use of high-pressure microfluidization can further reduce the particle size of the system and improve the penetration rate.

[0111] Example 1 and Comparative Example 2 are analyzed in depth, Figure 3 and Figure 4 The content distribution diagram of the samples of Comparative Example 2 and Example 1 at different depths of the skin is shown in Figure 2. Figure 3 It can be seen that the ordinary 10-peptide composition of Comparative Example 3 penetrates into the stratum corneum in small amounts within 0.5h and 1h, breaks through the stratum corneum into the active epidermis within 2h, and only continues to penetrate in the stratum corneum and the active epidermis within 4h and 6h.

[0112] It can be seen that the long-acting mild anti-wrinkle supramolecular polypeptide composition can break through the stratum corneum into the active epidermis in small amounts within 0.5h, continue to penetrate in the stratum corneum and the active epidermis within 1h, 2h and 4h, and break through the active epidermis into the dermis within 6h. Figure 4 This shows that the long-acting mild anti-wrinkle supramolecular polypeptide composition prepared by the present application has the ability to penetrate the dermis, and can comprehensively improve the efficacy of the composition in anti-wrinkle, anti-inflammatory and soothing.

[0113] Efficacy test of experimental example 4

[0114] In order to verify the real use effect of the long-acting mild anti-wrinkle supramolecular polypeptide composition of the present application, the samples of Example 1, Comparative Example 2, Comparative Example 3 and Comparative Example 4 were prepared into essence milk according to the formula of Table 7 by the following steps:

[0115] A phase was added to the oil phase pot, and stirred and heated to 80-82℃; B phase was added to the water phase pot, and stirred and heated to 80-82℃; A phase and B phase were added to the emulsification pot, and homogenized for 5min; stirred and cooled to 60-62℃, C phase was added, homogenized for 5min, stirred and cooled to 40℃, D phase was added, and stirred evenly.

[0116] Table 7 Formula of essence milk

[0117]

[0118]

[0119] ​

[0120] The product of Example 1 and Comparative Example 4 was added to the soothing test, and the products of Example 1, Comparative Example 2 and Comparative Example 3 were added to the anti-wrinkle test.

[0121] (1) Soothing test

[0122] The soothing test was performed using the pain inflammation COX-2 enzyme inhibition effect evaluation method. The control holes and sample holes were set in a 96-well plate, and the sample to be tested and other solutions were added according to Table 8, and after mixing, incubated at 37°C for 10 min. After adding COX-2 Probe (5 μL) in each hole, quickly add COX-2 Substrate working solution, mix well, and incubate at 37°C for 30 min in the dark, then perform fluorescence test, and calculate the inhibition rate according to the formula.

[0123] Table 8 Soothing experimental group components

[0124]

[0125]

[0126] Inhibition rate calculation formula:

[0127] Inhibition rate % = (RFU (100% enzyme activity control group) - RFU (sample)) / (RFU (100% enzyme activity control group) - RFU (blank control)) * 100%

[0128] The test results are shown in Table 9 below:

[0129] Table 9 Soothing test results

[0130] Group Inhibition rate of COX-2 activity / % Example 1 68.25 Comparative example 4 22.88

[0131] As can be seen from the table, when the soothing peptide acetyl heptapeptide-4 is not added, the soothing anti-inflammatory effect of the cosmetic is poor, which is not conducive to the use of sensitive skin consumers, and there is a risk of causing skin discomfort. It is necessary to add the long-acting mild anti-wrinkle supermolecular peptide composition described in the present application to the soothing peptide for co-anti-wrinkle and anti-aging, which is conducive to the promotion of the composition and suitable for skin anti-aging for all skin consumers.

[0132] (2) Anti-wrinkle test

[0133] The anti-wrinkle test is divided into 4 groups, each group is participated by 10 volunteers aged 35-55 years old, before the test, the tester uses Visioline VL650 wrinkle tester to measure the wrinkle area of the face skin of the volunteer before the test, recorded as S0, then the tester evenly applies 0.5g of the sample to the face skin of the volunteer, the frequency is twice a day (once in the morning and once in the evening), and records the wrinkle area of the face skin after 0, 7, 14, 21, 28 days of continuous use, respectively, recorded as S t The reduction of the skin wrinkle area is calculated according to the following formula:

[0134] The reduction of the skin wrinkle area (%) = (S t -S0) / S0 * 100%

[0135] According to the above test scheme, the test results are shown in Table 10.

[0136] Table 10 Reduction of skin wrinkle amount

[0137]

[0138] According to the analysis of the data in Table 10, the anti-wrinkle effect of the supramolecular composition using the supramolecular solvent (betaine-citric acid) is more obvious, the anti-wrinkle effect of the serum added with the example 1 and the comparative example 3 is obviously higher than that of the serum added with the comparative example 2; and the further treatment with high pressure microfluidization is more conducive to the reduction of wrinkles, the anti-wrinkle effect of the serum added with the example 1 is obviously higher than that of the serum added with the comparative example 3. This effect is derived from the product obtained by the synergistic penetration of the supramolecular solvent and the self-assembly supramolecular polypeptide, and the treatment with high pressure microfluidization can further reduce the particle size of the system and improve the penetration rate, so that the product can enter the dermis layer to play the efficacy. It can be seen that the efficiency of reducing the number of wrinkles of the serum added with the example 1 can still be maintained at about 4% after 21 days, while the efficiency of the serum added with the comparative example 2 and the comparative example 3 is only 0.1% and 3.1%, which shows that the long-acting mild anti-wrinkle supramolecular polypeptide composition prepared by the application has better long-acting anti-aging effect.

[0139] The above only describes the preferred embodiments of the present application and is not used to limit the present application. For those skilled in the art, the present application can have various modifications and changes. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A long-lasting, mild, anti-wrinkle supramolecular polypeptide composition, characterized in that, Composed of raw materials with the following weight percentages: botulinum-like polypeptide 0.013%-0.015%, collagen growth promoting peptide 0.061%-0.065%, soothing peptide 0.01%-0.015%, anti-inflammatory peptide 0.005%-0.008%, supramolecular ionic liquid 5%-8%, active ingredient 32%-35%, and the rest being water; The botulinum-like polypeptide comprises arginine / lysine polypeptide and acetyl hexapeptide-1; The collagen growth promoting peptide comprises palmitoyl tripeptide-1, palmitoyl tripeptide-5, palmitoyl pentapeptide-4, tripeptide-1, decapeptide-4, and hexapeptide-9; The soothing peptide is acetyl heptapeptide-4; The anti-inflammatory peptide is palmitoyl tetrapeptide-7; The supramolecular ionic liquid is one or two of glycerol-betaine, betaine-propylene glycol, and betaine-citric acid; The active ingredient is one or two of 1,2-hexanediol, glycerol, and 1,2-pentanediol; The preparation method of the long-acting mild anti-wrinkle supramolecular polypeptide composition comprises: Take palmitoyl tripeptide-1, palmitoyl tripeptide-5, and palmitoyl pentapeptide-4, dissolve them in water, ultrasonic dispersion, adjust the pH value to 4-5.5, and obtain solution 1; Take tripeptide-1, decapeptide-4, hexapeptide-9, arginine / lysine polypeptide, and acetyl hexapeptide-1, dissolve them in water, and obtain solution 2; Add solution 2 to solution 1 under stirring, and stand at room temperature for 3-6 h to obtain solution 3; Mix the supramolecular ionic liquid and the active ingredient, ultrasonic dispersion, add palmitoyl tetrapeptide-7 and acetyl heptapeptide-4, heat at 30-50℃ for 10-20 min, and obtain solution 4; Add solution 3 to solution 4 under stirring, and perform high-pressure microjet treatment.

2. The method for preparing the long-acting, mild, anti-wrinkle supramolecular polypeptide composition as described in claim 1, characterized in that, Comprise: Take palmitoyl tripeptide-1, palmitoyl tripeptide-5, and palmitoyl pentapeptide-4, dissolve them in water, ultrasonic dispersion, adjust the pH value to 4-5.5, and obtain solution 1; Take tripeptide-1, decapeptide-4, hexapeptide-9, arginine / lysine polypeptide, and acetyl hexapeptide-1, dissolve them in water, and obtain solution 2; Add solution 2 to solution 1 under stirring, and stand at room temperature for 3-6 h to obtain solution 3; Mix the supramolecular ionic liquid and the active ingredient, ultrasonic dispersion, add palmitoyl tetrapeptide-7 and acetyl heptapeptide-4, heat at 30-50℃ for 10-20 min, and obtain solution 4; Add solution 3 to solution 4 under stirring, and perform high-pressure microjet treatment.

3. The method for preparing the long-acting, mild, anti-wrinkle supramolecular polypeptide composition as described in claim 2, characterized in that, The stirring speed is 50-500 rpm; Or, the pressure of the high-pressure microjet is 10000-20000 psi, and the treatment is performed 2-3 times.

4. Use of the long-acting mild anti-wrinkle supramolecular polypeptide composition according to any one of claims 1 in the preparation of cosmetics.

Images